The global transcriptomics market size was valued at USD 8.2 billion in 2025 and is projected to grow from USD 8.63 billion in 2026 to USD 12.97 billion by 2034, registering a CAGR of 5.23% during the forecast period from 2026 to 2034. North America dominated the transcriptomics market with a market share of 42.3% in 2025.
Transcriptomics is the study and analysis of an organism’s complete set of RNA transcripts to understand gene expression, regulation, and cellular activity under specific biological conditions. It uses technologies such as RNA sequencing and microarrays to identify and measure RNA molecules. Transcriptomics is widely used in disease research, drug discovery, precision medicine, biotechnology, and molecular biology to identify biomarkers, understand biological mechanisms, and support the development of targeted therapies.
Download a Free Sample To learn more about this report,
Growing Shift Toward High-Throughput Spatial Transcriptomics
The transcriptomics market is increasingly moving from conventional RNA sequencing toward spatial approaches that measure gene expression while retaining the location of cells within tissue. Spatial information allows researchers to understand how neighboring cell populations interact and how molecular activity changes across tumors, organs, and other complex structures. Increasing throughput is making these workflows suitable for larger tissue areas and research cohorts rather than isolated experiments. High-throughput spatial analysis is therefore becoming an important part of transcriptomics market trends.
In April 2026, 10x Genomics introduced its Atera spatial platform for whole-transcriptome in situ analysis. The system is designed to process more than 100 million cells annually on a single instrument while providing single-cell gene-expression information across large tissue samples.
Increasing Integration of Transcriptomics With Proteomics
Researchers increasingly want to measure RNA and proteins within the same biological specimen instead of analyzing individual molecular layers separately. Combining these datasets can reveal whether changes in gene expression translate into corresponding cellular functions and can provide a more complete view of disease pathways and treatment responses. Same-sample analysis also reduces variability associated with comparing separate tissue sections. RNA-protein integration is consequently expanding the transcriptomics industry toward multidimensional biological profiling.
In April 2025, Bruker expanded the CosMx Spatial Molecular Imager with same-slide multiomics capabilities that combine approximately 19,000 whole-transcriptome RNA targets with up to 76 protein targets at single-cell and subcellular resolution.
Expansion of Single-Cell Research Increases Sequencing Requirements
Bulk RNA sequencing averages molecular signals across many cells and can hide rare populations or important differences between individual cells. Researchers are therefore increasingly using single-cell transcriptomics to investigate immune responses, developmental pathways, tumor heterogeneity, and disease-associated cell states. Larger studies require technologies capable of processing substantially more cells while maintaining reliable molecular information. Expansion of single-cell research is therefore strengthening transcriptomics market demand.
In February 2025, Parse Biosciences expanded its Evercode single-cell portfolio with scalable workflows capable of processing experiments ranging from thousands to millions of cells without requiring specialized microfluidic instrumentation.
Large RNA Datasets Create Bioinformatics Bottlenecks
Modern single-cell experiments generate large expression matrices that require quality control, normalization, clustering, annotation, differential-expression analysis, and biological interpretation. Laboratories can generate sequencing information faster than they can analyze it when computational infrastructure or specialist bioinformatics expertise is limited. Storage and processing requirements also rise as studies include more cells and samples. Computational complexity can consequently restrain transcriptomics market growth despite improvements in sequencing throughput.
In July 2025, QIAGEN expanded its Digital Insights bioinformatics capabilities for complex omics interpretation. Its knowledge infrastructure contains more than 100,000 manually curated molecular relationships that can be used to connect large experimental datasets with biological pathways and disease mechanisms.
Expansion of Three-Dimensional Transcriptomic Mapping
Most spatial workflows analyze thin tissue sections, providing only a two-dimensional view of biological structures that naturally exist in three dimensions. Direct 3D analysis can reveal cellular neighborhoods, tissue boundaries, tumor invasion patterns, and molecular gradients that may be missed when separate sections are reconstructed computationally. This creates new applications in neuroscience, developmental biology, and cancer research. Three-dimensional molecular mapping can therefore help technology providers increase transcriptomics market share.
In February 2026, Stellaromics launched Pyxa for 3D spatial transcriptomics in intact tissue. The platform can analyze specimens up to 100 micrometers thick while retaining three-dimensional cellular and molecular organization.
Preserving RNA Quality During Sample Preparation
RNA degrades more easily than DNA, making sample collection, storage, fixation, extraction, and processing critical to transcriptomic accuracy. Degraded molecules can reduce transcript detection and introduce biases that are particularly problematic when researchers compare clinical samples collected under different conditions. Archived tissue presents an additional difficulty because fixation can fragment or chemically modify RNA. Maintaining usable molecular information across diverse sample types therefore remains a major challenge as the transcriptomics market size expands into translational research.
In May 2026, Takara Bio expanded its SMART-Seq transcriptomics workflows for challenging and low-input specimens, supporting RNA analysis from inputs reaching the picogram range and addressing applications where only very small quantities of high-quality biological material are available.
Consumables Segment Dominated the Market with 45.8% Share in 2025
The consumables segment dominated the global transcriptomics market with a 45.8% market share in 2025, valued at USD 3.76 billion. Its leading position is supported by the recurring need for reagents, assay components, sequencing materials, sample preparation products, and other consumable inputs used throughout transcriptomic workflows. Growing research activity and the increasing use of high-throughput molecular analysis are contributing to sustained demand for these products.
Instruments and software & services continue to support transcriptomics workflows by enabling sample processing, sequencing, data analysis, and interpretation. Their adoption is expanding as laboratories and research organizations incorporate increasingly sophisticated transcriptomic techniques into their research programs.
Request Customizationto receive a tailored report.
Next-Generation Sequencing (NGS) Segment Dominated the Market with 46.9% Share in 2025
The next-generation sequencing segment dominated the global transcriptomics market with a 46.9% market share in 2025, valued at USD 3.85 billion. NGS supports high-throughput analysis of RNA and gene expression, making it an important technology for transcriptome profiling and molecular research. Its ability to analyze large volumes of genetic information efficiently is supporting continued adoption across research, drug development, and disease-related studies.
Polymerase chain reaction, microarray, and other technologies continue to serve specialized transcriptomic research requirements. These approaches remain relevant for targeted analysis, gene expression studies, validation, and applications where specific analytical workflows are preferred.
Diagnostics and Disease Profiling Segment is Projected to Register the Fastest Growth at a CAGR of 14.6%
The diagnostics and disease profiling segment is projected to register the fastest growth at a CAGR of 14.6% during the forecast period. Increasing use of transcriptomic analysis to investigate disease mechanisms, identify molecular signatures, and improve understanding of patient biology is supporting demand in this area. Advances in sequencing and computational analysis are further enabling researchers to examine gene-expression patterns associated with different diseases.
Drug discovery and development remains a major application area, as transcriptomic data can help researchers understand biological pathways, identify potential therapeutic targets, and evaluate molecular responses to treatments. Other applications also contribute to market expansion across diverse biological research activities.
Biotechnology Companies Segment is Projected to Register the Fastest Growth at a CAGR of 15.2%
The biotechnology companies segment is projected to register the fastest growth at a CAGR of 15.2% during the forecast period. Biotechnology firms are increasingly applying transcriptomics to biomarker discovery, therapeutic research, molecular characterization, and development of innovative biological products. The growing integration of sequencing and computational technologies is expanding the ability of these companies to generate and interpret complex gene-expression data.
Academic and research institutes remain a major end-user group, supported by extensive use of transcriptomics in basic biological research and disease studies. Pharmaceutical companies also continue to adopt transcriptomic approaches to support drug discovery, development, target identification, and investigation of treatment responses.
Speak to an Analystto discuss market opportunities.
The North American transcriptomics market accounted for 42.3% of the global market, reaching USD 3.47 billion in 2025, and is projected to grow at a CAGR of 11.8% during the forecast period. The region's leading position is supported by advanced genomics research infrastructure, strong biotechnology and pharmaceutical industries, increasing investments in molecular research, and growing adoption of transcriptomic technologies for drug discovery, precision medicine, and disease research.
The United States represents a major market in North America. Its strong biotechnology ecosystem, extensive genomics research activities, advanced sequencing capabilities, and substantial pharmaceutical R&D investments continue to support transcriptomics market growth.
Canada's established life sciences sector, growing genomics research capabilities, and increasing adoption of advanced molecular analysis technologies continue to support regional market development.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific transcriptomics market accounted for 22.7% of the global market, reaching USD 1.86 billion in 2025, and is projected to grow at a CAGR of 15.4% during the forecast period. The region records the fastest growth among the listed markets, driven by expanding biotechnology industries, increasing healthcare investments, growing genomics research, and rising adoption of advanced sequencing and molecular analysis technologies.
China represents a major market within the Asia Pacific. Expanding biotechnology and pharmaceutical R&D, increasing genomics research, and growing investments in advanced sequencing technologies continue to support transcriptomics market growth.
Japan's advanced life sciences ecosystem, strong biomedical research capabilities, and increasing adoption of molecular analysis technologies continue to support demand for transcriptomics solutions.
India's expanding biotechnology sector, growing genomics research capabilities, and increasing adoption of advanced molecular diagnostics continue to create opportunities for transcriptomics market development.
Europe's transcriptomics market accounted for 26.4% of the global market, reaching USD 2.16 billion in 2025, and is expected to register a CAGR of 12.1% during the forecast period. The region's growth is supported by increasing investments in genomics and biotechnology research, expanding precision medicine initiatives, and growing adoption of advanced sequencing and transcriptomic analysis technologies.
Germany represents a major European market. Its strong pharmaceutical and biotechnology industries, advanced research infrastructure, and growing focus on molecular diagnostics and precision medicine continue to support transcriptomics adoption.
The United Kingdom's established genomics research ecosystem, pharmaceutical R&D capabilities, and increasing focus on personalized healthcare continue to create opportunities for transcriptomics technologies.
Latin America's transcriptomics market accounted for 5.1% of the global market, reaching USD 0.42 billion in 2025, and is expected to grow at a CAGR of 10.6% during the forecast period. Increasing investments in healthcare and biotechnology, expanding genomics research, and growing adoption of molecular analysis technologies continue to support regional market development.
Brazil represents a major regional market. Its expanding biotechnology and biomedical research sectors, increasing genomics activities, and growing adoption of advanced sequencing technologies continue to support transcriptomics market growth.
The Middle East & Africa transcriptomics market accounted for 3.5% of the global market, reaching USD 0.29 billion in 2025, and is anticipated to grow at a CAGR of 9.8% during the forecast period. Healthcare infrastructure development, increasing investments in biotechnology and genomics, and growing adoption of advanced molecular technologies continue to support regional market expansion.
The UAE's investments in advanced healthcare, biotechnology, and genomics research continue to support demand for transcriptomics technologies.
Saudi Arabia's healthcare modernization, growing life sciences ecosystem, and increasing focus on genomic medicine continue to create opportunities for transcriptomics market development.
The global transcriptomics market is highly competitive, with leading life sciences, genomics, sequencing, molecular biology, and biotechnology companies competing through RNA sequencing, microarray technologies, single-cell transcriptomics, spatial transcriptomics, library preparation, bioinformatics, and gene expression analysis solutions. The major players in the market include Pacific Biosciences of California Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., QIAGEN, Bio-Rad Laboratories Inc., Takara Bio Inc., PerkinElmer Inc., Fluidigm Corporation, F. Hoffmann-La Roche, Merck & Co. Inc., Promega Corporation, RNA Connect, Becton, Dickinson and Company, Bio-Techne Corporation, and others.
Industry participants are focusing on developing high-throughput and high-resolution transcriptomic technologies that enable researchers to analyze gene expression, RNA modifications, cellular heterogeneity, and molecular pathways with greater sensitivity and accuracy. Companies are investing in next-generation sequencing, single-cell RNA sequencing, spatial transcriptomics, long-read sequencing, advanced sample preparation, and bioinformatics platforms to expand transcriptomic research capabilities. Growing demand for precision medicine, cancer research, biomarker discovery, drug development, and personalized therapeutics is encouraging pharmaceutical companies, research institutions, and biotechnology organizations to adopt advanced transcriptomics technologies.
Illumina Inc. is one of the leading companies in the global transcriptomics market, providing next-generation sequencing platforms, consumables, library preparation technologies, and informatics solutions that enable researchers to perform comprehensive RNA sequencing and gene expression analysis. Its sequencing technologies support applications including bulk RNA sequencing, single-cell analysis, transcriptome profiling, and other genomic research workflows.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com